Cargando…
Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines
Small molecule Bruton’s tyrosine kinase (BTK) inhibitors have been developed for the treatment of various haemato-oncological diseases, and ibrutinib was approved as the first BTK inhibitor for anticancer therapy in 2013. Previous reports proved the receptor kinase human epidermal growth factor rece...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140101/ https://www.ncbi.nlm.nih.gov/pubmed/36913160 http://dx.doi.org/10.1007/s10637-023-01346-7 |